Back to top
more

Charles River Laboratories International (CRL)

(Delayed Data from NYSE)

$180.96 USD

180.96
830,357

+2.38 (1.33%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $180.89 -0.07 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Charles River (CRL) Q1 Earnings Top, Gross Margin Falls

by Zacks Equity Research

Charles River (CRL) Q1 results highlight 9.8% organic revenue growth, driven by strength across all three segments.

Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Charles River (CRL) delivered earnings and revenue surprises of 1.48% and 0.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

MedTech Stocks' Q1 Earnings Due on May 4: CRL, IDXX & NUVA

by Urmimala Biswas

MedTech companies' results are likely to reflect a rebound in the base business. Let's see how CRL, IDXX and NUVA fare this time.

Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Charles River (CRL) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Robust global demand for the research model and multiple initiatives to expedite the discovery process are likely to have contributed to Charles River's (CRL) first-quarter results.

Charles River (CRL) Buys Explora BioLabs to Expand in CRO Space

by Zacks Equity Research

Explora BioLabs' business is likely to complement and expand the Charles River's (CRL) CRADL operation within the broader Insourcing Solutions business.

Here's Why You Should Retain Charles River (CRL) Stock For Now

by Zacks Equity Research

Investors are optimistic about Charles River's (CRL) strong segmental growth and notable partnerships.

Charles River Laboratories (CRL) is a Top-Ranked Value Stock: Should You Buy?

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Is Charles River (CRL) Down 3.4% Since Last Earnings Report?

by Zacks Equity Research

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CoDiagnostics, Inc. (CODX) Surges 13.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Neena Mishra headshot

Inflation Beneficiary ETFs in Focus as Prices Soar

by Neena Mishra

These ETFs invests in assets that benefit from inflation

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why You Should Retain Charles River (CRL) Stock For Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) on robust demand in Biologics Testing Solutions and Microbial Solutions businesses.

Charles River (CRL) DSA Arm Sees Growth, Cell Supply Sluggish

by Zacks Equity Research

The acquisitions of Cognate BioServices and Vigene Biosciences contribute to the growth of Charles River's (CRL) Manufacturing Solutions arm.

Here's Why You Should Hold on to IDEXX (IDXX) Stock for Now

by Zacks Equity Research

Robust domestic and international performances by the CAG arm are driving IDEXX's (IDXX) fourth-quarter top line.

Tandem Diabetes (TNDM) to Offer Insulin Delivery With Smartphone

by Zacks Equity Research

Tandem Diabetes' (TNDM) t:connect is the first-ever app on both iOS and Android operating systems to receive FDA clearance for insulin delivery from a personal smartphone.

Charles River (CRL) Q4 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Robust demand for research models, particularly in China, as well as higher revenues from research model services aid Charles River (CRL) in Q4.

Charles River Laboratories (CRL) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Charles River (CRL) delivered earnings and revenue surprises of 2.89% and 1.52%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Sanghamitra Saha headshot

Land on 5 Winning Stocks With the Overlooked Rising P/E Trick

by Sanghamitra Saha

Stocks with rising P/E often proves to be an intriguing investing idea.

Here's Why You Should Hold on to Thermo Fisher (TMO) Stock Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher's (TMO) better-than-expected fourth-quarter results and impressive COVID-19 response-related revenues.

Charles River (CRL) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

The acquisitions of Vigene Biosciences and Cognate are likely to have a full-quarter favorable impact on Charles River's (CRL) Q4 Manufacturing Support revenues.

Charles River Laboratories (CRL) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad's (BIO) strong growth within Life Science and Clinical Diagnostics segments across all regions.

Medtronic (MDT) Reports First Procedure in Europe With Hugo RAS

by Zacks Equity Research

Medtronic's (MDT) Hugo RAS system was utilized to perform robotic prostatectomy at OLV Hospital in Aalst, Belgium.

Is Charles River (CRL) a Solid Growth Stock? 3 Reasons to Think " Yes "

by Zacks Equity Research

Charles River (CRL) could produce exceptional returns because of its solid growth attributes.